Tardive Dyskinesia (TD) is a neurological movement disorder typically characterized by repetitive, involuntary movements of the jaw, lips, and tongue....
Orsini Specialty Pharmacy, a leading independent specialty pharmacy focused on rare diseases and gene therapies, has been selected by Provention Bio,...
Mucopolysaccharidosis (MPS) is an inherited metabolic disease in which the body does not produce enough enzymes to break down sugars into simpler...
The National Association of Healthcare Quality (NAHQ) proudly established Healthcare Quality Week as a dedicated time to celebrate the profession and...
Dealing with a rare disease or complex condition can be exhausting, stressful, frustrating, costly, and at times, frightening. Even the most resilient...
X-linked hypophosphatemia (XLH) is an inherited rare disorder that affects 1 in 20,000 individuals and is characterized by low levels of phosphate in...
Duchenne muscular dystrophy (DMD) is a genetic form of muscular dystrophy characterized by the progressive weakness and degeneration of the skeletal...
Pompe disease is estimated at 1 in every 40,000 births. It is a rare, inherited disorder caused by the buildup of a complex sugar called glycogen and...
Orsini Specialty Pharmacy, the leading independent specialty pharmacy focused on rare diseases and gene therapies, has been selected by Marinus...
Orsini Specialty Pharmacy, a leader in rare diseases and gene therapies, has been chosen by Alnylam Pharmaceuticals as a specialty pharmacy partner for...
Orsini is a leading independent national specialty pharmacy accredited by ACHC, JCAHO, URAC, and VIPPS. The services we provide allow patients, physicians, payors, and manufacturers to improve care, simplify processes, and achieve better outcomes.
Now In Stock: ADZYNMA (ADAMTS13, recombinant-krhn), for patients with cTTP
Orsini Specialty Pharmacy Selected as Distribution Partner for Adzynma (ADAMTS13, recombinant-krhn), a Newly Approved Treatment for an Ultra-Rare Blood Clotting Disorder
Orsini Specialty Pharmacy Partners with Amicus Therapeutics to Dispense New Therapy for the Treatment of Late-Onset Pompe Disease
Orsini Specialty Pharmacy Names Darin DeCarlo Chief Growth Officer
Orsini Specialty Pharmacy Selected to be the Exclusive Specialty Pharmacy Partner for VEOPOZ™ (pozelimab-bbfg), the First and Only Treatment for CHAPLE Disease
.jpg?width=1754&height=637&name=SP_Logo_Color_RGB%202020update%20(1).jpg "Orsini Specialty Pharmacy Logo"){kind=logo}
![[Whitepaper] Payor Considerations When Choosing a Specialty Pharmacy](https://no-cache.hubspot.com/cta/default/7642930/d6329582-47a1-404d-b2a8-63c2637a9807.png)